Alain Bruno

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

Sylvia Julien, Ana Merino‐Trigo, Ludovic Lacroix et al. · Clinical Cancer Research · 2012 · 365 citations · Full text

Medicine, Cancer Biology, Oncology +16

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Patrick Casara, James Davidson, Audrey Clapéron et al. · Oncotarget · 2018 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Zoltán Szlávik, Márton Csékei, Attila Paczal et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

Mike F. Burbridge, Céline Bossard, Carine Saunier et al. · Molecular Cancer Therapeutics · 2013 · 87 citations

Medicine, Oncology, Pharmacology +17